IL10 and central nervous system cancer: Additionally, in the subgroup analyses of ages for IL‐10 (Table 3), we found that increased circulating IL‐10 [SMD 0.69 (95% CI: 0.13‐1.25; P = .016)] was significantly associated with glioma risk for age < 60 years, and decreased circulating IL‐10 [SMD −1.54 (95% CI: −2.11 to −0.97; P = .000)] was significantly associated with glioma risk for age ≥ 60 years.